Chimerix hammers out an emergency PhII Ebola study for antiviral
October 28, 2014 -- Chimerix has outlined plans for a small Phase II study of its powerful antiviral brincidofovir as a counterpunch to Ebola.
In recent weeks the biotech ($CMRX) has added details on its study design listed on clinicaltrials.gov. The trial calls for 50 patients aged 2 months to 75 years old who test positive for the lethal Ebola virus. While the online site notes that no recruiting is being done yet, Chimerix lists a company contact for the study along with plans to start off Ebola patients with a 200-mg dose of brincidofovir (CMX001), to be followed up with four 100-mg doses over the next two weeks. The study is slated to wrap up a little more than a year from now.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.